• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Home
  • LinkedIn
  • Twitter

  • About Us
    • Overview
    • Executive Committee
    • Board Of Directors
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • shRNA
      • shARC Platform
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Careers
  • Contact Us
  • Home
  • Pipeline

Pipeline

Pipeline

 

Celyad Oncology has developed a diversified pipeline of next-generation allogeneic and autologous CAR T candidates which have provided proof-of-concept of our technologies and targets.

AML: acute myeloid leukemia; BCMA:B-cell maturation antigen;  GvHD: graft-versus-host disease; mCRC: metastatic colorectal cancer; MDS: myelodysplastic syndrome; MM: multiple myeloma; NKG2D: Natural killer group 2D; PoC: proof-of-concept; shARC: shRNA armored CAR; shRNA: short hairpin ribonucleic acid; TIM: T-cell receptor inhibitory molecule

# Evaluated in the Phase I studies THINK NCT03018405, LINK NCT03370198, SHRINK NCT03310008 and DEPLETHINK NCT03466320; ## Evaluated in the Phase I study CYCLE-1 NCT04167696; § Evaluated in the Phase I studies alloSHRINK NCT03692429, and KEYNOTE-B79 NCT04991948; §§ Evaluated in the Phase I study IMMUNICY-1 NCT04613557

LEARN ABOUT OUR shRNA PLATFORM

Footer

Celyad Oncology

Celyad Oncology Logo
  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.

  • Cookie Policy |
  • Privacy Policy |
  • Terms of Use